Panel discussions
Intellectual property is a key driver of the enterprise value, and its licensing-in and -out is a business model in the life sciences industry. Licensing with strategic partners allows companies to strengthen product development, create synergies, and enter new markets. Experts from Swiss and international companies will discuss what needs to be considered when evaluating licensing strategies and what are the opportunities and challenges in the long term.
May 6, 14:00-14:45, room MCH Lounge
| Name | Position | Institution |
|---|---|---|
| Dr. Lorenza Ferrari Hofer | Partner | Schellenberg Wittmer Ltd |
| Name | Position | Institution |
|---|---|---|
| Peter Droc | Business Unit Head Drug Product Services | Lonza AG |
| Dr. Michael R. Hübner | Director, Country Lead EIP Switzerland | Johnson & Johnson Innovation |
| Michael Pitzner | General Counsel & Compliance Officer, SVP Legal and Business Development | Molecular Partners AG |
Schellenberg Wittmer Ltd is your leading Swiss business law firm with more than 150 lawyers in Zurich and Geneva, and an office in Singapore. We take care of all your legal needs – transactions, advisory, disputes.
Our headquarters in Zurich and Geneva, covering the whole of Switzerland, provide a comprehensive range of legal services to a worldwide client base of domestic and international companies and entrepreneurs.
Our Singapore office provides a gateway to the Asian market, enabling us to assist clients with their inbound and outbound investments in Asia. We also represent clients in connection with international arbitration matters in all major Asian cities.
At Schellenberg Wittmer, we strive to meet your needs by providing commercially focused, dedicated legal advice of the highest quality.
